Nombre del producto:4-(Trifluoromethyl)pyridine

IUPAC Name:4-(trifluoromethyl)pyridine

CAS:3796-24-5
Fórmula molecular:C6H4F3N
Pureza:95%
Número de catálogo:CM120878
Peso molecular:147.1

Unidad de embalaje Stock disponible Precio($) Cantidad
CM120878-10g in stock ƚŌŌ
CM120878-25g in stock ŌǪǙ
CM120878-100g in stock ƚǸƿŌ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :3796-24-5
Fórmula molecular:C6H4F3N
Punto de fusión:-
Código de sonrisas:FC(C1=CC=NC=C1)(F)F
Densidad:
Número de catálogo:CM120878
Peso molecular:147.1
Punto de ebullición:
Nº Mdl:MFCD00153289
Almacenamiento:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Relacorilant
Corcept completes enrollment in phase 3 Gradient trial of Relacorilant in patients with Adrenal Cushing’s Syndrome. Cushing's disease or hypercortisolism is a rare endocrine disorder that occurs when a pituitary adenoma makes excessive cortisol. Cortisol exerts its functions by binding to the glucocorticoid receptor (GR).
Relacorilant is a selective glucocorticoid receptor modulator (SGRM) in clinical development to prevent the effects of high cortisol. Relacorilant is being studied in various serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome.